SEC Tracker
Get the app

Nektar Therapeutics NKTR

Nektar Therapeutics: reports quarterly results, announces exit or restructuring costs and 2 other items

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Reports quarterly results (2.02)
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Nektar Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Aura Biosciences AURA public float $321M, Jun 30, 2025
  2. Prothena PRTA public float $327M, Jun 30, 2025
  3. Altimmune ALT public float $327M, Jun 30, 2025
  4. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  5. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.